EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

BACKGROUND: Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been proven to be beneficial f...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Hao, Li, Yongwen, Yuan, Yin, Li, Weiting, Zhang, Hongbing, Zhang, Zihe, Shi, Ruifeng, Liu, Minghui, Liu, Chao, Chen, Chen, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716470/
https://www.ncbi.nlm.nih.gov/pubmed/33276757
http://dx.doi.org/10.1186/s12885-020-07667-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716470/
https://www.ncbi.nlm.nih.gov/pubmed/33276757
http://dx.doi.org/10.1186/s12885-020-07667-7

Ejemplares similares